Psychedelics are drawing renewed attention in medical and legal circles, but experts remain divided on how quickly the U.S. should expand access. At a recent Harvard Law School event hosted by the Petrie-Flom Center, scholars and advocates debated whether to prioritize therapeutic potential or scientific caution.
Former Navy pilot Matthew Buckley described his recovery from trauma through ibogaine and 5-MeO-DMT, urging faster access for veterans. Meanwhile, ethicist Holly Fernandez Lynch argued that psychedelic medicine must meet the same standards as any other drug, warning against premature commercialization. As researcher David Yaden noted, rigorous, well-funded studies remain essential to understanding benefits and risks.
Read the full story from Harvard University via Medical Xpress.
The latest news on the legalization of controversial botanicals.
